Elicio Therapeutics Financials - Benzinga

Elicio Therapeutics Inc

ELTXNASDAQ

Trade with Public

Trade with Public

$1.84

-0.04-2.13%

al cierre: Sep 25, 5:00 PM EST

$1.85

0.0150.82%

After hour: 4:00 PM EST

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Elicio Therapeutics Financials

Elicio Therapeutics (ELTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q1 EPS $(0.65) Misses $(0.47) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.47) by 41.3 percent. This is a 25.29 percent increase over losses of $(0.87) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q4 EPS $(0.45) Beats $(0.47) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.47) by 3.23 percent. This is a 55.88 percent increase over losses of $(1.02) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate

Benzinga Newsdesk

PRO
Elicio Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 3.13 percent decrease over losses of $(0.64) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 24.35 percent increase over losses of $(1.15) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved